Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes

Drug Metabolism and Disposition

Volumn 34, Issue 6, 2006, Pages 1041-1046

  Zandvliet, Anthe S ^a,e   Copalu, William ^b   Schellens, Jan H M ^c,d   Beijnen, Jos H ^a,d   Huitema, Alwin D R ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b EISAI CO LTD   (Japan)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CARBONATE DEHYDRATASE; INDISULAM; PLASMA PROTEIN;

ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; ERYTHROCYTE; HUMAN; HUMAN CELL; PLASMA PROTEIN BINDING; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARBON RADIOISOTOPES; CARBONIC ANHYDRASES; CLINICAL TRIALS, PHASE I; ERYTHROCYTE MEMBRANE; ERYTHROCYTES; HUMANS; MODELS, BIOLOGICAL; PROTEIN BINDING; SERUM ALBUMIN; SULFONAMIDES;

EID: 33646775727     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.008326     Document Type: Article

References (26)

1. Abbate F, Casini A, Owa T, Scozzafava A, and Supuran CT (2004) Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett 14:217-223.
2. Bayne WF, Chu LC, and Theeuwes F (1979) Acetazolamide binding to two carbonic anhydrase isoenzymes in human erythrocytes. J Pharm Sci 68:912-913.
3. Beal SL, Boeckman AJ, and Sheiner LB (1988) NONMEM User's Guides. University of California at San Francisco, San Francisco, CA.
4. Demir N, Demir Y, Bakan E, and Kufrevioglu OI (1997) A different structural feature for carbonic anhydrases in human erythrocytes. Prep Biochem Biotechnol 27:279-287.
5. Dittrich C, Dumez H, Calvert H, Hanauske A, Faber M, Wanders J, Yule M, Ravic M, and Fumoleau P (2003) Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin Cancer Res 9:5195-5204.
6. Fukuoka K, Usuda J, Iwamoto Y, Fukumoto H, Nakamura T, Yoneda T, Narita N, Saijo N, and Nishio K (2001) Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Investig New Drugs 19:219-227.
7. Fumoleau P, Viens P, Cottu PH, De Grève J, Marty M, Delaloge S, Miles D, O'Reilly S, Wardley A, Schmid P, et al. (2003) A multi center phase II study of E7070, a chloroindolyl-sulfonamide anticancer agent in anthracycline and taxane pretreated breast cancer, in the 26th San Antonio Breast Cancer Symposium; 2003 Dec 3-6; San Antonio, TX. Abstract 535.
8. Haddad RI, Weinstein LJ, Wieczorek TJ, Bhattacharya N, Raftopoulos H, Oster MW, Zhang X, Latham VM Jr, Costello R, Faucher JL, et al. (2004) A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin Cancer Res 10:4680-4687.
9. Hasegawa T, Hara K, and Hata S (1994) Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro. Drug Metab Dispos 22:377-382.
10. Mainwaring PN, Van Cutsem E, Van Laethem JL, Propper D, Twelves C, Bridgewater J, Audhuy B, Carmichael J, Punt CJA, Cassidy J, et al. (2002) A multicentre randomised phase II study of E7070 in patients with colorectal cancer who have failed 5-fluorouracil-based chemotherapy (Abstract). Proc Am Soc Clin Oncol 21:611.
11. Mariani G, Strober W, Keiser H, and Waldmann TA (1976) Pathophysiology of hypoalbuminemia associated with carcinoid tumor. Cancer 38:854-860.
12. Oda Y, Owa T, Sato T, Boucher B, Daniels S, Yamanaka H, Shinohara Y, Yokoi A, Kuromitsu J, and Nagasu T (2003) Quantitative chemical proteomics for identifying candidate drug targets. Anal Chem 75:2159-2165.
13. Owa T, Yoshino H, Okauchi T, Yoshimatsu K, Ozawa Y, Sugi NH, Nagasu T, Koyanagi N, and Kitoh K (1999) Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem 42:3789-3799.
14. Ozawa Y, Sugi NH, Nagasu T, Owa T, Watanabe T, Koyanagi N, Yoshino H, Kitoh K, and Yoshimatsu K (2001) E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer 37:2275-2282.
15. Punt CJA, Fumoleau P, van de Walle B, Faber MN, Ravic M, and Campone M (2001) Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann Oncol 12:1289-1293.
16. Raftopoulos H, Escudier B, Renshaw G, Lara PN, Dutcher J, Nanus D, Petrylak DP, and Sacris L (2004) A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with inoperable and/or metastatic renal cell carcinoma (RCC) (Abstract). J Clin Oncol 22 (Suppl):4629.
17. Raymond E, ten Bokkel Huinink WW, Taieb J, Beijnen JH, Faivre S, Wanders J, Ravic M, Fumoleau P, Armand JP, and Schellens JHM (2002) Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. J Clin Oncol 20:3508-3521.
18. Singh J and Wyeth P (1991) The enzyme-inhibitor approach to cell-selective labelling-I. Sulphonamide inhibitors of carbonic anhydrase as carriers for red cell labelling: in vitro uptake of pIBS by human red blood cells. Int J Rad Appl Instrum A 42:251-259.
19. Smyth JF, Aamdal S, Awada A, Dittrich C, Caponigro F, Schoffski P, Gore M, Lesimple T, Djurasinovic N, Baron B, et al. (2005) Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol 16:158-161.
20. Talbot DC, Norbury C, Slade M, von Pawel J, Bosquee L, Ellis PA, Gatzemeier U, and Ravic M (2002) A phase II and pharmacodynamic study of E7070 in patients with non-small cell lung cancer (NSCLC) who have failed platinum-based chemotherapy (Abstract). Proc Am Soc Clin Oncol 21:1306.
21. Terret C, Zanetta S, Roche H, Schellens JHM, Faber MN, Wanders J, Ravic M, and Droz JP (2003) Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). Eur J Cancer 39:1097-1104.
22. van den Bongard HJ, Pluim D, Waardenburg RC, Ravic M, Beijnen JH, and Schellens JHM (2003) In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood. Anticancer Drugs 14:405-410.
23. van Kesteren C, Mathot RAA, Raymond E, Armand JP, Dittrich C, Dumez H, Roche H, Droz JP, Punt CJA, Ravic M, et al. (2002) Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol 20:4065-4073.
24. van Kesteren C, Zandvliet AS, Karlsson MO, Mathot RAA, Punt CJA, Armand JP, Raymond E, Huitema ADR, Dittrich C, Dumez H, et al. (2005) Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Investig New Drugs 23:225-234.
25. World Medical Association (2000) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 284:3043-3045.
26. Yamada Y, Yamamoto N, Shimoyama T, Horiike A, Fujisaka Y, Takayama K, Sakamoto T, Nishioka Y, Yasuda S, and Tamura T (2005) Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. Cancer Sci 96:721-728.